Tox Card: Cardiovascular Drug Effects on the Action Potential and ECG

Authors: Todd Duppong, MD (PGY2, Emergency Medicine Residency Program, Morristown Medical Center), Cynthia Santos, MD (Assistant Professor Emergency Medicine, Medical Toxicology, Rutgers NJMS) // Edited by:  Alex Koyfman, MD (@EMHighAK, EM Attending Physician, UTSW / Parkland Memorial Hospital), and Brit Long, MD (@long_brit, EM Attending Physician, San Antonio Military Medical Center)

Case:

A 35 year old lady intentionally overdosed on her prescription medication for fibromyalgia and recent diagnosis of depression. ECG shows sinus tachycardia (rate of 150), QRS ≥120 ms, and R wave elevation in aVR ≥3 mm. What are the action potential phases responsible for ECG changes? What ECG changes are associated with cardiotoxicity? Which medications cause changes in action potential/ECGs?

Background:

An electrocardiogram (ECG) is a rapid diagnostic tool frequently used for evaluation because of the predictable cardiotoxic effects from specific drugs. Serial ECGs should be performed in addition to a good history, physical examination, and evaluation of clinical findings/toxidrome to guide course and treatment.

Figure 1: Represents ECG and time associated action potential phases.[1]

Pearls:

  • Phase 0 is a rapid depolarization which results from sodium entering the cell. Sodium channel blockers result in ECG changes with a widened QRS complex.
  • Examples of Sodium channel blockers include (phase 0): lidocaine, phenytoin, bufatoxin, tetrodotoxin, TCA, antihistamines
  • ECG changes for sodium channel blockers: QRS widening, RBBB, right axis deviation, ventricular tachycardia/fibrillation, bradycardia, asystole, ST-T changes
  • Class 1b antidysrhythmic (lidocaine, phenytoin, etc.) do NOT affect the QRS width because of the fast association/dissociation kinetics.

Figure 2: Common sodium channel blockers which cause QRS widening.[1]

  • Phase 1 is the initial repolarization (overshoot). The voltage-sensitive sodium channels close and potassium ions efflux from the cell.
  • Phase 2 is the plateau phase which balances the calcium influx and potassium efflux.
  • Examples of Potassium channel blockers include (phase 2 and 3): antipsychotics and methadone.

Figure 3: Potassium channel blockers result in QT prolongation followed by torsade de pointe.[1]

  • Phase 3 is the repolarization phase which results from the L-type calcium channels closing while the rectifier potassium channels open resulting in potassium efflux and net positive outward current.
  • ECG changes for potassium channel blockers: QT prolongation, T- or U-wave abnormalities, premature ventricular beats, torsade de pointes, sinus tachycardia.

 Figure 4: Common potassium channel blockers. [2]

  • Phase 4 is the resting membrane potential which is maintained by the Na-K-ATPase and maintains the negative membrane potential at around -90 mV.
  • ECG changes for Sodium-Potassium ATPase inhibitors:
    • Excitant activity: atrial/junctional premature beats, atrial tachycardia, atrial flutter/fibrillation, accelerated junctional rhythms, premature ventricular beat, bigeminy and multifocal, ventricular tachycardia, bi-directional ventricular tachycardia/fibrillation.
    • Suppressant activity: sinus bradycardia, sinoatrial block, type I second degree AV block, type II second degree AV block, complete AV block, bundle branch blocks.
    • Combination: atrial tachycardia with AV block, sinus bradycardia with junctional tachycardia, Wenckebach with junctional premature beats, regularization of ventricular rhythm with atrial fibrillation.
  • Examples of Sodium-Potassium ATPase inhibitors include (phase 4): cardiac glycosides (digoxin, digitalis, budodienolides).
  • Hypokalemia potentiates digitalis toxicity.

  

References:

  1. Santos C., Manini A. Electrocardiographic Interpretation. In: Part 3: Investigations of cardiocirculatory failure. New York, NY: Mount Sinai School of Medicine.
  2. Lionte C., Bolaga C., Sorodoc L. Toxic and Drug-Induced Changes of the Electrocardiogram. Advances in Electrocardiograms – Clinical Applications. 15: 271-296.
  3. Yates C., Manini A. Utility of electrocardiogram in drug overdose and poisoning: theoretical considerations and clinical implications. Current Cardiology Review. 2012; 8: 137-151.

Share This:

1 thought on “Tox Card: Cardiovascular Drug Effects on the Action Potential and ECG”

  1. Pingback: Länkar v41-42 | Internmedicin

Leave a Comment

Your email address will not be published. Required fields are marked *

emDOCs subscribes to the Free Open Access Meducation (FOAMed) initiative. Our goal is to inform the global EM community with timely and high-yield content about what providers like YOU are seeing and doing daily in your local ED.

WRITE FOR EMDOCS

We are actively recruiting both new topics and authors.
This project is rolling and you can submit an idea or write-up anytime!
Contact us at editors@emdocs.net

news, headlines, newsletter

Join our Newsletter

Keep up to date on all of the latest new articles, studies, and Podcasts.
 ofera solutii complete de reparatii, montaj si intretinere pentru toate modelele de masini de spalat rufe.